meta|Evidence - COVID-19
click on circles to display study description...
chloroquine (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
chloroquine
450 mg x2 day 1, then 450 mg/d for 4 days
placebo
COVID-19 mild to moderate
double-blind
1 center, Brazil
found in Axfors et al meta-analysis
hydroxychloroquine (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
hydroxychloroquine
placebo
COVID-19 mild to moderate
double blind
international
found in Axfors et al meta-analysisTerminated (Rate of enrollment too slow to allow completion in a reasonable timeframe
hydroxychloroquine (n=125) vs. standard of care (n=129)
randomized controlled trial some concerns about risk of bias
Favipiravir and Hydroxychloroquine
Favipiravir: 1800 mg twice daily for one day, followed by 800mg (total days of therapy is 10 days or till hospital discharge)Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily.
standard of care
COVID-19 mild to moderate
open label
9 centers, Saudi Arabia
Moderate or Severe confirmed COVID-19
Trial stopped for futility after the first interim analysis
hydroxychloroquine (n=360) vs. standard of care (n=180)
randomized controlled trial high risk of bias
Hydroxychloroquine
Standard of care plus hydroxychloroquine 400mg twice daily on day 1, then 200mg twice daily for the next 5 days.
Standard of care
SOC treatment comprised daily oral vitamin C (2 g), oral zinc (50 mg), oral vitamin D(alfacalcidol 1 µg), and oral acetaminophen (for body aches and fever).
2:1 ratio. All patients received standard of care.
COVID-19 mild to moderate
Adult patients (18-80) with mild COVID-19 (PCR confirmed infection) and hospitalized.
Open-label.
Single-center; Pak Emirates Military Hospital, Rawalpindi, Pakistan.
Progression of disease was defined by the development of fever >101°F for >72 hours, shortness of breath with minimal exertion, derangement of basic laboratory parameters (ALC < 1000 or raised CRP), or appearance of infiltrates on X-ray chest.
hydroxychloroquine (n=15) vs. standard of care (n=15)
randomized controlled trial high risk of bias
hydroxychloroquine 400mg
hydroxychloroquine 400mg per day for 5 days
standard of care
COVID-19 mild to moderate
open-label
China
paper in chinese
hydroxychloroquine (n=31) vs. standard of care (n=31)
randomized controlled trial high risk of bias
hydroxychloroquine 400mg
additional oral HCQ (hydroxychloroquine sulfate tablets, Shanghai Pharma) 400 mg/d (200 mg/bid) between days 1 and 5
standard of care
COVID-19 mild to moderate
(RT-PCR) positive of SARS-coV-2; chest CT with pneumonia; saO2/SPO2 ratio > 93% or paO2/FIO2 ratio > 300 mmhg under room air
open-label
China, single center
there is some changes in the publication compared to the registry record (open control in place of placebo, sample size and the primary endpoint changed that does rule out the possibility of a selective publication bias)
hydroxychloroquine (n=221) vs. standard of care (n=227)
randomized controlled trial some concerns about risk of bias
hydroxychloroquine at a dose of 400 mg twice daily
hydroxychloroquine [400mg 2x/day, 12/12h] for 7 days
standard of care
The use of glucocorticoids, other immunomodulators, antibiotic agents, and antiviral agents was allowed
3 arms: hydroxychloroquine plus azythromycin, hydroxychloroquine monotherapy and standard of care
COVID-19 mild to moderate
open-label
Brazil, 55 sites
Randomization was performed in blocks of six and was stratified according to the use or nonuse of supplemental oxygen at the time of randomization
powered by vis.js Network